Article
Oncology
Fengguang Guo, Jugal K. Das, Koichi S. Kobayashi, Qing-Ming Qin, Thomas A. Ficht, Robert C. Alaniz, Jianxun Song, Paul De Figueiredo
Summary: This study demonstrates that live attenuated bacterial treatment can improve antitumor immunity by remodeling the tumor microenvironment, overcoming cancer resistance to chimeric antigen receptor T-cell therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Yukiko Yamaguchi, Jackson Gibson, Kevin Ou, Lupita S. Lopez, Rachel H. Ng, Neena Leggett, Vanessa D. Jonsson, Jelani C. Zarif, Peter P. Lee, Xiuli Wang, Catalina Martinez, Tanya B. Dorff, Stephen J. Forman, Saul J. Priceman
Summary: This study reveals an alternative mechanism by which the combination of CAR T cells and immune checkpoint blockade modulates the immune landscape of solid tumors to enhance therapeutic efficacy of CAR T cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Francesco De Sanctis, Alessia Lamolinara, Federico Boschi, Chiara Musiu, Simone Caligola, Rosalinda Trovato, Alessandra Fiore, Cristina Frusteri, Cristina Anselmi, Ornella Poffe, Tiziana Cestari, Stefania Cane, Silvia Sartoris, Rosalba Giugno, Giulia Del Rosario, Barbara Zappacosta, Francesco Del Pizzo, Matteo Fassan, Erica Dugnani, Lorenzo Piemonti, Emanuela Bottani, Ilaria Decimo, Salvatore Paiella, Roberto Salvia, Rita Teresa Lawlor, Vincenzo Corbo, Youngkyu Park, David A. Tuveson, Claudio Bassi, Aldo Scarpa, Manuela Iezzi, Stefano Ugel, Vincenzo Bronte
Summary: PDAC tumors exhibit strong immunosuppressive characteristics that limit the success of immunotherapy. Research shows that reprogramming the tumor microenvironment by intervening in RNS production can enhance the efficacy of immune-based treatments.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Ravikumar Muthuswamy, A. J. Robert McGray, Sebastiano Battaglia, Wenjun He, Anthony Miliotto, Cheryl Eppolito, Junko Matsuzaki, Tsuji Takemasa, Richard Koya, Thinle Chodon, Brian D. Lichty, Protul Shrikant, Kunle Odunsi
Summary: Resident memory CD8 T cells, characterized by their ability to reside in peripheral tissues, play a crucial role in adaptive sentinel activity and amplifying immune responses. The study focused on the chemotactic mechanisms governing the localization, retention, and residency of memory CD8 T cells in the ovarian tumor microenvironment. Results indicated that CXCR6 is a key marker for resident memory tumor-specific CD8 T cells, with its deficiency resulting in reduced retention in tumor tissues and poor control of ovarian cancer. Further research is needed to explore the potential of utilizing CXCR6 to enhance resident memory responses in cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Xin-Wen Zhang, Katrin Huck, Kristine Jaehne, Frederik Cichon, Jana K. Sonner, Friederike Ufer, Simone Bauer, Marcel Seungsu Woo, Ed Green, Kevin Lu, Michael Kilian, Manuel A. Friese, Michael Platten, Katharina Sahm
Summary: DC vaccination is an effective adjuvant for cancer immunotherapies, and enhancing DC migration towards the tumor microenvironment could increase therapeutic efficacy. Expression of Arc/Arg3.1 facilitates DC migration towards tumors and shapes the tumor immune microenvironment, suggesting it as a potential novel therapeutic target for improving DC vaccine efficacy.
Article
Oncology
Peter M. Carlson, Ravi B. Patel, Jen Birstler, Matthew Rodriquez, Claire Sun, Amy K. Erbe, Amber M. Bates, Ian Marsh, Joseph Grudzinski, Reinier Hernandez, Alexander A. Pieper, Arika S. Feils, Alexander L. Rakhmilevich, Jamey P. Weichert, Bryan P. Bednarz, Paul M. Sondel, Zachary S. Morris
Summary: The combination of external beam radiation therapy (EBRT) and intratumoral immunocytokine (IC) generates an effective in situ vaccine (ISV) against GD2-positive murine tumors. However, ISV does not produce an adequate response against distant tumors. Additional radiation therapy (RT) to all sites of disease may augment the antitumor responses to ISV.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Katie M. Campbell, Maneesha Thaker, Egmidio Medina, Anusha Kalbasi, Arun Singh, Antoni Ribas, Theodore Scott Nowicki
Summary: The complementary use of bulk and spatial profiling allows for more accurate investigation of tumor specimens, particularly in addressing complex questions regarding immunotherapeutic mechanisms.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
A. J. Robert McGray, Jessie L. Chiello, Takemasa Tsuji, Mark Long, Kathryn Maraszek, Nicole Gaulin, Spencer R. Rosario, Suzanne M. Hess, Scott Abrams, Danuta Kozbor, Kunle Odunsi, Emese Zsiros
Summary: The therapeutic efficacy of cancer immunotherapies in ovarian cancer is limited. Researchers have developed T cells that secrete a bispecific T-cell engager targeting the folate receptor alpha commonly overexpressed in OC. These T cells efficiently lyse tumor cells and induce antitumor immunity. Preconditioning of T cells with cytokines improves therapeutic efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Ingunn M. Stromnes, Ayaka Hulbert, Meagan R. Rollins, Ryan S. Basom, Jeffrey Delrow, Patrick Bonson, Adam L. Burrack, Sunil R. Hingorani, Philip D. Greenberg
Summary: This study investigates the role of immune checkpoints in mediating functional dysfunction of engineered T cells in pancreatic ductal adenocarcinoma (PDA). The findings suggest that blockade of PD-1 signaling alone is not enough to overcome the dysfunction of TCR engineered T cells in PDA. Contributions from both the differentiation pathways induced during the T cell engineering process and intratumoral suppressive mechanisms render engineered T cells dysfunctional.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Huanpeng Chen, Yuying Yang, Yuqing Deng, Fengjiao Wei, Qingyu Zhao, Yongqi Liu, Zhonghua Liu, Bolan Yu, Zhaofeng Huang
Summary: This study developed CAR-T cells that can secrete a CD47 blocker, enhancing the therapeutic efficacy of CAR-T cells in solid tumor therapy. The results showed that these CAR-T cells significantly reduced tumor burden, prolonged survival, and modulated the tumor microenvironment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Aiqin Gao, Xia Liu, Wenli Lin, Jingnan Wang, Shuyun Wang, Fusheng Si, Lan Huang, Yangjing Zhao, Yuping Sun, Guangyong Peng
Summary: ILT4 is highly expressed in human tumor cells and tissues, negatively associated with clinical outcomes. Tumor-derived ILT4/PIR-B directly induces cell senescence in naive/effector T cells in vitro and in vivo through MAPK ERK1/2 signaling. Blocking tumor-derived PIR-B can reprogram tumor metabolism, prevent senescence development in tumor-specific T cells, and enhance antitumor immunity in both breast cancer and melanoma mouse models.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Medicine, Research & Experimental
Sasan Ghaffari, Nima Rezaei
Summary: This article discusses the functions and roles of eosinophils in the tumor microenvironment, as well as their interactions with tumor cells, immune cells, and gut microbiota. Studies have shown that eosinophils play a dual role in tumor development through the release of mediators and interactions with other immune cells. Understanding the characteristics and behaviors of eosinophils can aid in the design of novel therapeutic strategies targeting tumor cells.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Yunfeng Pan, Xueru Song, Yue Wang, Jia Wei
Summary: Immunotherapies have significantly improved the prognosis of cancer patients by mobilizing host immunity against cancer cells, but their efficacy depends on local immune conditions. Current strategies to improve the cold tumor microenvironment are unsatisfactory. Nanoparticle-based therapies show promise in remodeling the tumor microenvironment by stimulating immune responses.
Review
Immunology
Joey H. Li, Timothy E. O'Sullivan
Summary: NK cell dysfunction is a common occurrence during tumor development due to immunosuppressive mechanisms. Understanding the spatiotemporal dynamics of these mechanisms is crucial for optimizing NK cell therapy for cancer.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Jeong A. Park, Madelyn Espinosa-Cotton, Hong-fen Guo, Sebastien Monette, Nai-Kong Cheung
Summary: This study demonstrates that using anti-VEGF antibodies can significantly improve the therapeutic efficacy of T cell immunotherapies by increasing HEVs and promoting the infiltration of cytotoxic CD8(+) TILs.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Young Seob Kim, Hyun Jin Park, Jung Hwa Park, Eun Ji Hong, Gun-Young Jang, In Duk Jung, Hee Dong Han, Seung-Hyun Lee, Manh-Cuong Vo, Je-Jung Lee, Andrew Yang, Emily Farmer, T. -C. Wu, Tae Heung Kang, Yeong-Min Park
Article
Oncology
Ju-Won Roh, Jung Eun Choi, Hee Dong Han, Wei Hu, Koji Matsuo, Masato Nishimura, Ju-Seog Lee, Sun Young Kwon, Chi Heum Cho, Jongseung Kim, Robert L. Coleman, Gabriel Lopez-Bernstein, Anil K. Sood
CANCER BIOLOGY & THERAPY
(2020)
Article
Engineering, Biomedical
Ji Eun Won, Tae In Wi, Chan Mi Lee, Ju Hyeong Lee, Tae Heung Kang, Jeong-Won Lee, Byung Cheol Shin, YeongJoo Lee, Yeong-Min Park, Hee Dong Han
Summary: A new injectable hydrogel system for sustained drug release at the tumor site has been developed in this study. The combined therapeutic efficacy of the hydrogel system and a nanoparticle-based immunotherapeutic vaccine for melanoma cancer was demonstrated, showing a potential combination approach for chemo- and immunotherapies for cancer treatment.
ACTA BIOMATERIALIA
(2021)
Article
Plant Sciences
Heewon Song, Ji Eun Won, Jeonggeun Lee, Hee Dong Han, YoungJoo Lee
Summary: The present study investigated the effects of Korean Red Ginseng (KRG) on DEHP-induced inflammation in endometrial cancer Ishikawa cells and a mouse model of endometriosis. KRG was found to suppress the inflammatory response and inhibit the activation of signaling pathways associated with inflammation. The results suggest that KRG may have potential therapeutic applications in the treatment of endometrial cancer and endometriosis.
JOURNAL OF GINSENG RESEARCH
(2022)
Article
Engineering, Biomedical
Sung Eun Lee, Chan Mi Lee, Ji Eun Won, Gun-Young Jang, Ju Hyeong Lee, Sang Hyeon Park, Tae Heung Kang, Hee Dong Han, Yeong-Min Park
Summary: This study demonstrates a selective nanocarrier system that enhances cytotoxic T cell immunity against tumor-specific antigens, increases survival rates of immune-activating cells, and reduces tumor mass by decreasing immune-suppressive cells and anti-inflammatory cytokines. Combining the nanocarrier system with other ICIs further amplifies the anticancer immunity of interferon gamma+ (IFN-gamma) CD8+ T cells.
Article
Nanoscience & Nanotechnology
Ji Eun Won, Yeongseon Byeon, Tae In Wi, Jae Myeong Lee, Tae Heung Kang, Jeong Won Lee, Byung Cheol Shin, Hee Dong Han, Yeong-Min Park
ACS APPLIED BIO MATERIALS
(2019)